Angiopeptin;(Synonyms: 血管抑肽)
Angiopeptin 是生长抑素的环状八肽类似物,是一种 sst2/sst5 受体部分激动剂,IC50 值分别为 0.26 nM 和 6.92 nM。Angiopeptin 可以抑制生长激素释放和胰岛素样生长因子-1 (IGF-1) 产生。Angiopeptin 抑制腺苷酸环化酶或刺激细胞外酸化。Angiopeptin 具有用于冠状动脉粥样硬化研究的潜力。
Angiopeptin Chemical Structure
CAS No. : 113294-82-9
规格 |
|
是否有货 |
|
100 mg |
; |
询价 |
; |
250 mg |
; |
询价 |
; |
500 mg |
; |
询价 |
; |
* Please select Quantity before adding items.
Angiopeptin 的其他形式现货产品:
Angiopeptin TFA
生物活性 |
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research[1][2].
|
IC50 Target |
IC50: 0.26 nM (sst2) and 6.92 nM (sst5)[1][2]
|
体外研究 (In Vitro) |
Angiopeptin (0.1 nM- 10 μM; for 1 h) acts as a partial agonist (pEC50=6.57) with a maximum response of 423% at 3 μM on the release of tritium on CHO hsst2 cells[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
体内研究 (In Vivo) |
Angiopeptin (20 and 50μg/kg; i.h.) significantly inhibits neointimal formation[1]. Angiopeptin (20 μg/kg; per day) significantly inhibits coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
分子量 |
|
Formula |
|
CAS 号 |
|
Sequence Shortening |
|
中文名称 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
参考文献 |
-
[1]. Lundergan CF, et al. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol. 1991;17(6 Suppl B):132B-136B.
[2]. Alderton F, et al. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol. 2001;132(3):760-766.
|